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INTRODUCTION
Inorganic phosphate (Pi) is an essential nutrient
required for cellular metabolism and skeletal min-
eralization. It is well established that both parathy-
roid hormone (PTH) and 1,25-dihydroxy vitamin D3
(1,25(OH)2D3) regulate calcium homeostasis. It is
also widely thought that molecules involved in cal-
cium homeostasis mediate phosphate homeostasis
(1-3). However, recent studies have demonstrated
the existence of a novel Pi regulatory pathway that
is independent of the classic mode of calcium regula-
tion (1-3). A group of factors have been shown to
function as major regulators of phosphate homeosta-
sis, suggesting the existence of an elaborate network
of humoral interactions and feedback loops that in-
volve numerous organs including intestine, kidney
and bone. Fibroblast growth factor 23 (FGF23) has
been identified as a phosphaturic factor that is
mainly produced in the bone (4, 5). FGF23 is known
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to promote renal Pi excretion by decreasing its re-
absorption within the proximal tubules and simul-
taneously reducing plasma 1,25(OH)2D3 levels by
decreasing its biosynthesis and increasing its me-
tabolism (6). FGF23 requires the cofactor klotho
to bind with high affinity and to signal efficiently
through its cognate FGF receptor. Klotho and FGF
receptor 1 (IIIc) form a heterodimeric receptor for
FGF23 (7, 8). FGF23 is reported to also be regu-
lated by the phosphate regulating gene with ho-
mologies to endopeptidases on the X-chromosome
(PHEX) and dentin matrix protein 1 (DMP-1) (8).
The kidney is a major regulator of phosphate ho-
meostasis, and its phosphate reabsorption capacity
has been shown to either increase or decrease in
order to accommodate phosphate requirements (9,
10). The solute carriers of three distinct renal so-
dium dependent phosphate transporters known as
SLC34A1 [NaPi-IIa/NPT2a], SLC34A3 [NaPi-IIc/
NPT2c] and SLC20A2 [PiT-2] are specifically ex-
pressed on the brush border membrane of the renal
proximal tubules in both the mouse and rat (9-11).
Npt2a plays a major role in renal Pi reabsorption,
while Npt2c is important for Pi reabsorption in wean-
ing animals (12, 13). PiT-2 has also been shown to
be expressed in the proximal tubule cells (14). Re-
cently, several groups have demonstrated that a lack
of functional Npt2c protein in patients demonstrat-
ing hereditary hypophosphatemic rickets with hy-
percalciuria (HHRH) causes severe renal Pi wast-
ing and leads to hypophosphatemia (15-17). These
findings indicated that Npt2c may play an important
role in renal Pi re-absorption and bone mineraliza-
tion, and may be a key determinant of plasma Pi
concentration in human (15-17).
Npt2a knockout (KO) mice demonstrate lower
levels of renal Pi transport activity by 60% of those
of wild-type (WT) mice and hypophospatemia, but
not rickets/osteomalacia (18). We reported that in
Npt2a KO mice, Npt2c plays a major NaPi co-trans-
porter where it contributed to renal Pi re-absorption
(19). In adult Npt2a KO mice, Pi abnormalities were
largely rescued via the induction of renal Npt2c
transporters (19). Thus, it is good model to exam-
ine the role of Npt2c in Pi homeostasis. Cadmium
(Cd) is one of the most toxic metals observed in na-
ture. Phosphaturia has been documented in both
cadmium-exposed humans and experimental ani-
mals (20, 21). The toxic effects of cadmium on bone
were first observed after the outbreak of severe
Itai-itai disease (22, 23). Bone abnormalities asso-
ciated with Itai-itai disease include osteomalacia and
osteoporosis (24, 25). Accumulation of cadmium
within the renal cortex has been proposed to indi-
rectly and directly interfere with enzymes involved
in 1,25(OH)2D3 production and with transporters in-
volved in calcium and Pi homeostasis(26, 27). An in-
creased prevalence of osteomalacia and nephrolithi-
asis observed in patients with advanced Cd-induced
nephropathy is thought to be due to elevated frac-
tional urinary excretion of calcium and Pi caused by
impaired reabsorption of these ions (20). In regards
to nephropathy, Cd accumulation induced defects in
reabsorption at the level of the tubules (28). Clini-
cal features associated with Cd induced nephropa-
thy are similar to those exhibited during Fanconi’s
syndrome. Most recently, several groups have dem-
onstrated that iron-induced hypophosphatemic os-
teomalacia associated with marked FGF23 elevation
(29, 30). Ion-induced hypophosphatemia has also
been shown to be associated with impaired tubular
Pi reabsorption and reduced levels of 1,25(OH)2D3
(29, 30). However, FGF23 expression is reduced in
hypophosphatemia patients by Fanconi’s syndrome
(31).
In the present study, we investigated whether
FGF23 was involved in Cd induced nephropathy in
wild type (WT) and Npt2a-KO mice.
METHODS
Animals
Female C57BL/6 mice were purchased from the
Charles River Laboratories Japan (Yokohama, Ja-
pan), and male and female Npt2a+/- mice were pur-
chased from Jackson Laboratory (Bar Harbor, ME).
Crossing male and female Npt2a+/- mice yielded
Npt2a-/- mice. Npt2a+/+ were used as WT control
mice. Animals were housed in plastic cages and al-
lowed free access to standard laboratory food and
tap water. Nephrotoxicity was induced following a
subcutaneous injection of CdCl2 at a dose of 2 mg
Cd/kg daily for up to 14 days (32). Control animals
were injected with 0.9% sodium chloride (NaCl).
Mice were maintained under pathogen-free condi-
tions and handled in accordance with the Guidelines
for Animal Experimentation of the University of
Tokushima Faculty of Medicine.
Determination of Cd concentration in liver, kidney
and femur
The accumulation of Cd was measured using
flame atomic absorption spectrometry (AA-6400,
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Shimadzu, Tokyo, Japan). Samples were prepared
for measurement as previously reported with some
minor modifications (33). Briefly, each sample was
first dried to eliminate water at 110for 36 h. The
samples were then ashed at 250 for 3 h, 350
for 3 h and 550for 24 h. The ash samples were
then wet-digested in 1% hydrochloric acid (HCl).
Working concentrations of Cd were prepared from
a standard solution of Cd containing 100 mg/ml Cd
(Wako Japan).
Plasma and urine parameters
Two days prior to sacrifice, animals were individu-
ally placed in metabolic cages, and deprived of food
and water for 24 h. The concentration of plasma
and urinary inorganic calcium (Ca) and Pi were
then determined using the Calcium-E test (Wako,
Osaka, Japan) and the Phospha-C test (Wako), re-
spectively (34). Urinary and plasma creatinine (Cr)
concentration was determined using the LabAssay
Creatinine (Wako, Osaka, Japan). The concentration
of urine protein was determined using the BCATM
Protein Assay kit (Thermo Scientific IL, USA).
FGF23 protein concentration was determined using
the FGF-23 enzyme-linked immunosorbent assay
kit (ELISA, KAINOS Laboratories, Inc, Tokyo,
Japan) (34). Blood urea nitrogen (BUN) was deter-
mined using the UN-B test (Wako, Osaka, Japan),
and plasma 1,25(OH)2D3 was determined using the
1,25-(OH)2-Vitamin D ELISA kit (Immundiagnostik
AG, Bensheim, Germany) (35).
Preparation of brush border membrane vesicles and
transport assay
Brush-border membrane vesicles (BBMV) were
prepared from mouse kidney using the calcium
(Ca2+) precipitation method as described previously
(34, 36). BBMV 32P and Gly-Sar uptake was meas-
ured using the rapid filtration as described previ-
ously (37). Briefly, BBMV suspensions (20 μg/10
μl) were added to 90 μl of uptake solution containing
100 mM NaCl, 100 mM mannitol, 20 mM HEPES/
TRIS, 0.1 mM KH2 32PO4 for 32P uptake or 100 mM
NaCl, 100 mM mannitol, 20 mM HEPES/TRIS, 1
mM of un-labeled substrates, and [3H]Gly-Sar for
peptide uptake. At specific times, the uptake process
was quenched by adding ice-cold stop solution con-
taining 150 mM NaCl and 9 mM KH2PO4/K2HPO4
(pH 7.4). BBMV suspensions were then immedi-
ately poured onto pre-wetted membrane filters
(ADVANTEC, Tokyo, Japan) and washed three
times with ice-cold stop solution. 3 ml of Aquasol 2
(Perkin Elmer, Inc, MA) was then added to the
membrane filter and radioactivity counted using a
liquid scintillation counter (ALOKA, Tokyo, Japan).
Immunoblotting Analysis
BBMV samples were firstly heated at 95for 5
min in sample buffer in either the presence or ab-
sence of 5% 2-mercaptoethanol and subjected to
SDS-polyacrylamide gel electrophoresis. Separated
proteins were then transferred by electrophoresis
to a polyvinylidene difluoride transfer membrane
(Immobilon-P, Millipore Co., MA). The membranes
were incubated with affinity purified anti-Npt2a (1 :
4000) or Npt2c (1 : 1000) or Megalin (1 : 10000) an-
tibodies and then with horseradish peroxidase conju-
gated anti-rabbit IgG as the secondary antibody
(Jackson ImmunoResearch Laboratories, Inc.). The
signals were detected using the Immobilon Western
chemiluminescent HRP substrate (Millipore Co.)
(38). Anti-Megalin antibody was kindly provided
by Dr.Saito (Niigata University Graduate School of
Medical and Dental Sciences, Niigata, Japan).
Immunohistochemistry
Immunohistochemical analysis of the mouse kid-
ney was performed as described previously with
some minor modifications (12). Serial sections (5
μm) were incubated with affinity purified anti -
Npt2a (1 : 3000) or Npt2c (1 : 1000) antibody over-
night at 4. The sections were then treated with
Envision (+) rabbit peroxidase (Dako) for 30 min.
To detect immunoreactivity, the sections were
treated with ImmPACTTM DAB Peroxidase Substrate
(Funakoshi Co., Tokyo, Japan).
RNA extraction and quantitative PCR analysis
Total RNA was extracted from mouse tissues us-
ing ISOGEN (Nippon Gene, Tokyo, Japan), and
cDNA synthesized using the Moloney murine leu-
kemia virus reverse transcriptase (Superscript, In-
vitrogen, Carlsbad, CA), and oligo (dT)12-18 primer
(37). The reaction mixture contained 10 μl of SYBR
Premix Ex Taq (Perfect Real Time, Takara, Japan)
and specific primers. PCR primer sequences for
Npt2a and Npt2c (14), FGF23, DMP I and PHEX
(39) and for 1,25(OH)2D3 (6) have been previously
reported. The PCR conditions included denaturation
at 95for 10 s, followed by amplification with 40
cycles at 95for 5 s, and annealing at 60for 34 s.
Quantitative PCR was performed using the ABI
Prism 7500 (Applied Biosystems).
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Statistical Analysis
Data is presented as the meanstandard error
(S.E.). Differences between experimental groups
were determined by analysis of variance and p val-
ues0.05 were considered significant.
RESULTS
Accumulation of injected Cd in WT mice after 1 and
14 days
At 1, 3 and 14 days following Cd injection, the ac-
cumulation of Cd in various tissues was measured
using flame atomic absorption spectrometry. Sam-
ples were ashed and dissolved in 1% HCl. Cd solu-
tion (Wako Japan) was used as a standard. At 1 day
after injection, we observed a small accumulation
of Cd in the kidney and liver (Fig. 1 a and b). At 14
days, significantly high concentrations of Cd were
observed in the liver and kidney when compared
to the control mice (Fig. 1 a and b). These results
were consistent with those reported previously (40).
The level of Cd accumulation in the bone was not
significantly different to those observed between the
Cd and control mice (Fig. 1 c).
Time course after injection of Cd
WT mice were subcutaneously injected with Cd
every day for 14 days, and plasma and urine sam-
ples collected at 1, 3, 7 and 14 days after the injec-
tions. Plasma calcium levels did not demonstrate any
differences following the Cd injection (data not
shown), while plasma Pi and BUN were decreased
3 days after injection (Fig. 2 a and b). In contrast,
plasma FGF23 levels in the WT mice were signifi-
cantly increased at 3 and 14 days following Cd in-
jection (Fig. 2 c). Serum Cr levels, a marker of re-
nal function, were significant increase at 14 days
after injection (Fig. 2 d).
Fig. 1 Accumulation of Cd in the liver, kidney and femur of WT mice
Accumulation of Cd was measured using flame atomic absorption spectrometry. a) Liver, b) Kidney and c) Femur. Cd- : non-injected
mice Cd+ : Cd- injected mice. n=6-8. *p0.05 vs Cd- .
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Plasma and urine analysis of WT mice injected with
Cd for 14 days
The plasma and urine parameters of WT mice
after Cd injection are presented in Table 1. Plasma
and urine samples from WT mice were collected at
14 days. A urine sample was also collected 24 h
before sacrifice. Mice injected with Cd showed a
greater reduction in body weight when compared
to control mice, even though differences in food in-
take were not observed. Urine volume was no dif-
ference between control group and Cd injected
group (data not shown). Intoxicated mice demon-
strated a significant increase in plasma Ca and a
slight decrease in plasma Pi concentration. Plasma
BUN, plasma Cr, plasma FGF23 and plasma glucose
Fig. 2 Time course study of Cd injection for 14 days in WT mice
Plasma parameters of WT mice are presented in the graphs. Mice were injected with Cd for up to 14 days. Open bars represent the
non- injected mice and the closed bars represent the Cd-injected mice. a) plasma Pi levels, b) BUN, c) plasma FGF23 levels and d)
plasma Cre levels. n=6-8. *p0.05 vs Cd- .
Table 1. Body weight, food intake, plasma and urine biochemical measurements in WT mice
Cd- Cd+
% reduction of body weight 5.31.36 18.91.88*
food intake
(g/100 g body weight/day) 9.21
0.52 9.400.76
plasma Pi (mg/dL) 6.280.25 5.640.46
plasma Ca (mg/dL) 7.780.23 9.010.26*
plasma BUN (mg/ml) 25.00.88 46.28.47*
plasma Creatinine (mg/ml) 0.1320.02 0.3330.032*
plasma glucose (mg/dl) 210.97.61 154.76.42*
plasma 1,25(OH)2D3 (pg/ml) 43.650.14 43.088.09
plasma PTH (pg/ml) 33.33.52 42.45.7
plasma FGF23 (pg/ml) 66.94.34 171.540.9*
Pi/Creatinine 1.750.14 2.140.25*
Ca/Creatinine 0.130.01 0.240.05*
Protein/Creatinine 0.3140.039 0.4590.036*
n=6-8. Data represent the meansS.D. *p0.05 vs Cd-
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concentrations were significantly increased in the
Cd-injected mice when compared to those observed
in the control mice. However plasma PTH and
plasma 1,25(OH)2D3 indicated no change. These
findings suggested that Cd treatment in the mice
may cause low level renal dysfunction. In addition,
Cd-injected mice showed higher levels of urine Pi
and calcium, and a greater protein/creatinine ratio
when compared to controls.
Effects of Cd on the phosphate transporters Npt2a
and Npt2c in WT mice
To determine the effects of Cd on NaPi transport-
ers, we carried out immunoblotting, immunohisto-
chemistry and tracer studies on kidney BBMV. We
found that the NaPi co-transporter activity was de-
creased by 59.6% in the BBMV isolated from Cd
treated animals when compared to those from the
non-injected mice (Fig. 3 a). In addition, the pep-
tide transport activity did not change in the Cd-in-
jected mice when compared to those in the control
mouse group (Fig. 3 b). In order to investigate the
mechanisms underlying the reductions in phosphate
transport induced by Cd, we performed immunoblot-
ting and immunostaining analyses. Based on the im-
munoblotting of BBMV, we found that the expres-
sion of Npt2c was significantly decreased when com-
pared to the control mice (Fig. 3 c and e). In con-
trast, the protein levels of Npt2a and Megalin
showed no differences between the Cd-injected and
control mice (Fig. 3 c and d). A decrease in Npt2c
protein without change in Npt2a protein expression
was already seen at 3 days after Cd injection (Sup.
Fig. 1 a-c). Real-time PCR revealed that the Npt2a
Fig. 3 Effects of Cd on WT mouse kidney BBMV
Uptake of 32P and Gly-Sar was performed using BBMV prepared from WT mouse kidney. a) 32P and b) [3H]Gly-Sar. c) Western blotting
was performed in WT mice kidney BBMV in the presence of 2-mercaptoethanol. Left lane is Cd non- injected mice and right lane is
Cd-injected mice. Relative intensity of d) Npt2a and e) Npt2c against actin. mRNA expression of f) Npt2a and g) Npt2c was deter-
mined by real - time PCR. The results are shown as relative intensity against GAPDH. n=6-8. *p0.05 vs Cd- .
Sup. Fig. 1 Npt2a and Npt2c protein expression at day 3 of Cd injection in WT mice
Protein expression of Npt2a and Npt2c at day 3 of Cd injection was determined by Western blotting. a) Western blotting in the WT
mice kidney BBMV in the presence of 2-mercaptoethanol. Left lane, Cd non- injected mice (Cd-) ; Right lane, Cd- injected mice (Cd
+). Relative intensity of b) Npt2a and c) Npt2c against actin. n=5. *p0.05 vs Cd- .
F. Aranami, et al. Cadmium and FGF23100
and Npt2c mRNA levels were significantly de-
creased following Cd exposure (Fig. 3 f and g). In
addition, we also observed that Npt2a immunore-
activity was not altered between the Cd-injected and
control mice, while the intensity of the Npt2c sig-
nals were markedly decreased (Fig. 4 a-h). These
results were consisted with those reported for west-
ern blotting.
Accumulation of injected Cd in the Npt2a-KO mice
Accumulation of Cd in the Npt2a-KO mice in-
jected with Cd showed similar results to the WT
mice. That is, Cd was mainly accumulated in the
liver and kidney of the Npt2a-KO mice, while only
a small accumulation was observed in the bone
(Fig. 5 a-c).
Fig. 5 Accumulation of Cd in the liver, kidney and femur of Npt2a-KO mice
Accumulation of Cd was measured using flame atomic absorption. The numbers below the graph represent days after Cd injection.
Cd- : non- injected mice, Cd+ : Cd- injected mice. n=6-8. *p0.05 vs Cd- .
Fig. 4 Npt2a and Npt2c expression in the kidney
Expression of Npt2a and Npt2c in the kidney was analyzed by immunostaining. The kidney was fixed, embedded in paraffin, and 5-
μm sections collected. The top panel (a and c) represents Npt2a staining. The lower panel (b and d) represents Npt2c staining. e, f,
g and h show higher magnification micrographs of the highlighted areas in a-d. The scale bar represent 10 μm.
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Time course study of Npt2a-KO mice injected with
Cd
The plasma and urine parameters of Npt2a-KO
mice after Cd injection are presented in Table 2.
Plasma and urine samples were collected at 1, 3, 7
and 14 days post injection. Npt2a-KO mice demon-
strated low plasma FGF23 levels, a result that has
been reported previously (41). After injection of Cd,
plasma Pi and BUN levels were significantly de-
creased in the Npt2a-KO mice (Fig. 6 a and b). We
observed high plasma FGF23 concentrations at 3
and 14 days after injection of Cd in the WT mice.
While in the Npt2a-KO mice, elevation of plasma
FGF23 levels was observed at day 1 and day 14
(Fig. 6 c). In Npt2a-KO and WT mice, plasma Cr
levels were significant increase in 14 days after in-
jection (Fig. 6 d).
Fig. 6 Time course study of Cd injection for 14 days in Npt2a-KO mice
Plasma parameters of Npt2a-KO mice are presented in the graphs. Mice were injected with Cd for up to 14 days. The open bars
represent the non- injected mice and the closed bars represent the Cd-injected mice. a) plasma Pi, b) BUN, c) plasma FGF23 and d)
plasma Cre. n=6-8. *p0.05 vs Cd- .
Table 2. Body weight, food intake, plasma and urine biochemical measurements in Npt2a-KO mice
Cd- Cd+
% reduction of body weight 9.61.67 20.63.02*
food intake
(g/100 g body weight/day) 10.32
0.1 11.430.68
plasma Pi (mg/dL) 4.430.36 4.560.40
plasma Ca (mg/dL) 7.560.32 9.160.57*
plasma BUN (mg/ml) 28.21.22 65.412.8*
plasma Creatinine (mg/ml) 0.1820.012 0.3450.02*
plasma glucose (mg/dl) 195.97.71 142.810.3*
plasma 1,25(OH)2D3 (pg/ml) 41.5310.84 49.509.57
plasma PTH (pg/ml) 37.12.89 30.96.09
plasma FGF23 (pg/ml) N.D. 136.48.48*
Pi/Creatinine 5.042.62 9.935.34*
Ca/Creatinine 0.320.03 0.400.14
Protein/ Creatinine 0.1980.018 0.2590.032*
n=6-8. Data represent the meansS.D. N.D. : Not Detected *p0.05 vs Cd-
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Plasma and urine parameters in Npt2a-KO mice
injected with Cd
The plasma and urine parameters of Npt2a-KO
mice that were injected with Cd at days 14 and their
controls are presented in Table 2. Similar to the WT
mice, Npt2a -KO mice injected with Cd demon-
strated reduced body weight, even though differ-
ences in food intake were not observed. Urine vol-
ume was no difference between control group and
Cd injected group (data not shown). Npt2a-KO
mice that received Cd injections demonstrated a
significant increase in plasma Ca compared to the
control mice. Cd treated animals did not show any
changes in plasma Pi concentration when compared
to the control mice. In addition, Cd injection also
induced an increase in plasma BUN, plasma Cr,
plasma FGF23 and plasma glucose levels. While
plasma PTH and plasma 1,25(OH)2D3 did not show
any change. As for the urine parameters, Pi, calcium
and protein excretion shown in the creatinine ratio
were also increased.
Effects of Cd on the Pi transporters Npt2a and
Npt2c in Npt2a-KO mice
Similar to the WT mice, Npt2a-KO mice injected
with Cd showed a significant decrease (30.1%) in
NaPi co-transporter activity when compared to the
controls (Fig.7 a), but no change in peptide trans-
port activity (Fig. 7 b). To determine the levels of
Npt2c expression in the Npt2a-KO mice, we under-
took immunoblotting and immunostaining. Npt2a-
KO mice showed a reduction in renal Npt2c expres-
sion after injection of Cd (Fig. 7 c and d, and Fig. 8
a-d). Similar observations were also detected for
Npt2c mRNA expression (Fig. 7 e). As mentioned
Fig. 8 Immunostaining of the Npt2a-KO mice kidney
Expression of Npt2c in the kidney was analyzed by immunostain-
ing. The kidney was fixed, embedded in paraffin and 5-μm sec-
tions collected. a) represents a non- injected mouse and b) rep-
resents a Cd-injected mouse. parts c and d demonstrate higher
magnification areas from parts a and b.
The scale bar represent 10 μm.
Fig. 7 Effects of Cd on Npt2a-KO mice kidney BBMV
Uptake of phosphorus and Gly-Sar was performed using BBMV prepared from the WT mouse kidney. Samples were incubated in the
appropriate buffer for 60 or 10 s. a) 32P uptake and b) Gly-Sar uptake. c) Western blotting was performed on the Npt2a-KO mouse
kidney BBMV in the presence of 2-mercaptoethanol. Left lane is Cd non- injected mice and right lane is Cd-injected mice. d) Rela-
tive intensity of Npt2a and Npt2c against actin. e) mRNA expression of Npt2c was determined by real - time PCR. The results are
presented as relative intensity against GAPDH. n=6-8. *p0.05 vs Cd- .
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in WT mice this situation was already seen at 3 days
after Cd injection (Sup. Fig. 2 a-c).
PHEX, DMP1, FGF23 mRNA levels in the bone
As described above, Cd-injected mice demon-
strated increased plasma FGF23 levels. To further in-
vestigate FGF23 production, we determined the lev-
els of PHEX, DMP I and FGF23 mRNA expression
using real-time PCR. In both the WT and Npt2a-
KO mice, Cd-injected mice showed no significant
differences in gene expression when compared to
control mice (Sup. Fig. 3-I a-c and Sup. Fig. 3-II a-c).
DISCUSSION
In the present study, we investigated the effects
of Cd on the Npt2/FGF23/klotho system in the kid-
ney. The effects of Cd increased the levels of plasma
FGF23 in WT mice. We observed a simultaneous
decrease in renal phosphate transport activity. This
was also associated with a decrease in protein and
mRNA levels of the renal phosphate transporter
Npt2c, but not Npt2a, in WT mice. We also used
Npt2a-KO mice to further analyze the effects of Cd
on Npt2c. Injection of Cd into Npt2a knockout mice
resulted in severe hypophosphatemia and a signifi-
cant increase in plasma FGF23 levels. The elevation
of plasma FGF23 levels in the early stages after
injection of Cd is also thought to be important for
Cd-dependent hypophosphate expression.
The effects of Cd on Pi metabolism have been
previously reported by Herak-Kramberger et al.
(32). It is well established that Cd induces nephro-
toxicity due to its accumulation within the renal tu-
bules (42, 43). Previous animal models have dem-
onstrated that subcutaneous injection of CdCl2 into
Wistar-strain rats for 2 weeks induced nephrotox-
icity, a result that we have also shown in mice (32).
The treatment regime of daily Cd injections for 2
weeks represents a model of long-term Cd-induced
nephrotoxicity. Injection of Cd into rats resulted in
the inhibition of protein and phosphate urine excre-
tion, typical symptoms of Cd poisoning (32). These
rats also demonstrated a decrease in Npt2a expres-
sion in the kidney following Cd injection. It was also
demonstrated that expression of the water channel
Sup. Fig. 2 Npt2c protein expression at day 3 of Cd injection
in Npt2a-KO mice
Protein expression of Npt2a and Npt2c at day 3 of Cd injection
was determined by Western blotting.a) Western blotting was per-
formed on the Npt2a-KO mouse kidney BBMV in the presence
of 2-mercaptoethanol. Left lane is Cd non- injected mice and
right lane is Cd-injected mice. b) Relative intensity of Npt2c
against actin. n=5. *p0.05 vs Cd- .
Sup. Fig. 3 mRNA expression of FGF23 related factors in WT and Npt2a-KO mice
mRNA expression was determined using quantitative real - time PCR. Relative intensity is shown against Cd- expressed in WT mice
a) FGF23, b) DMP I, c) PHEX and for Npt2a-KO mice d) FGF23, e) DMP I, f) PHEX. n=6-8. *p0.05 vs Cd- .
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aquaporin 1 (AQP-1) remained unchanged in the
Cd-injected and non-injected rats. Although the pre-
cise expression levels of Npt2c were not determined
in the above study, these results suggest that the
effects of Cd intoxication on the kidney are mainly
limited to the Npt2a (32).
However, some of the results arising from our
present study are not consistent with those reported
previously (32, 44). Although our biochemical meas-
urements indicate that the observed proteinuria and
phosphaturia are in accordance with previous re-
ports (32, 44), and can be thought of as typical
symptoms for general Cd intoxication, the present
results of the kidney BBMV in the Cd-injected mice
show no decrease in Npt2a protein expression. This
result is not in accordance with previous findings.
Npt2a is thought to represent the main Pi trans-
porter that participates in Pi re-absorption in both
mice and rats. One possibility underlying these
discrepancies is that the rats used in the Herak-
Kramberger study and the mice used in our study
may have contained different Npt2a regulatory sys-
tems. However, further study is required to pre-
cisely determine the reasons causing these varying
results. Even though the our Cd-injected mice did
not show any reduction in Npt2a expression, a re-
sult that is not consistent with the previously re-
ported study, renal Pi transport activity in the Cd-
injected mouse BBMV did reveal a decrease. This
result suggests that even though Npt2a protein ex-
pression does not differ when compared to the con-
trol mice, Npt2a function may be directly inhibited
by Cd, while Npt2c function may be decreased by
FGF23 (45).
Another possibility for the differing response to
Cd between Npt2a and Npt2c may be due to differ-
ences in their expression patterns. In our previous
immunohistochemical studies, we demonstrated that
Npt2a protein was detected in the S1, S2 and S3 re-
gions of the proximal tubule cells (14). In addition,
it has been shown that Npt2c expression was re-
stricted to the S1 region of the proximal tubule cells
in the rat and mouse (46). Thus, the wide distribu-
tion of Npt2a protein may result in a greater resis-
tance to Cd toxicity. In the present study, we were
unable to investigate the levels of PiT-2 in the proxi-
mal tubule cells, as we could not obtain specific
antibodies directed against murine PiT-2. Further
studies are required to precisely clarify the role of
PiT-2 on Pi reabsorption after Cd injection.
An important finding in our study is that the
biphasic peak of FGF23 elevation is observed in
both WT and Npt2a-KO mice after Cd administra-
tion. In the early stage of Cd administration, plasma
PTH, Cr and BUN levels were not changed. How-
ever in the later stage of Cd administration, plasma
Cr and BUN levels were significantly increased.
These results suggest that second peak of FGF23
elevation may be due to renal dysfunction as re-
ported previously (47). In the analysis of the Npt2a
and Npt2c expression, Cd administration resulted
in a reduction of Npt2c protein in the renal proxi-
mal tubular cells. Even though there have been no
reports suggesting that Cd accumulates within the
kidney as early as 24 h after injection of Cd, we did
observe low levels of accumulation at this time.
Therefore, in the early stage of Cd administration
the reduction of renal Npt2c protein expression may
have occurred as a direct effect of increased plasma
FGF23 levels. Although FGF23 is known to func-
tion as a negative regulator of 1,25(OH)2D3 produc-
tion (48). In the WT and Npt2a-KO mice, plasma
1,25(OH)2D3 levels were not decreased following
injection of Cd, while the plasma FGF23 concentra-
tion was significantly increased. Measurement of the
enzymes related to 1,25(OH)2D3 production also re-
sulted in no significant differences. One possibility
for this result is that Cd directly disturbed FGF23-
dependent vitamin D regulation. Further studies are
required to define the precise role of Cd in vitamin
D/Pi metabolism.
Although we analyzed the expression of PHEX,
MEPE, DMP-1 and FGF23 mRNA levels in the
bone, we did not observe any obvious changes in
the expression of these genes. These findings sug-
gested that the production of FGF23 in the bone
was not stimulated by Cd administration. The
mechanisms underlying the elevated plasma FGF23
levels are currently unknown. Recently, Shimizu et
al. reported that saccharated ferric oxide induced
up-regulation of FGF23 levels and resulted in hy-
pophosphatemia (29). It has been hypothesized
that saccharated ferric oxide caused proximal tu-
bular dysfunction as the small size and neutral
charge of the drug allowed it to be filtered through
the glomeruli and be deposited in the proximal tu-
bules (49). Thus, as Cd-injected mice also demon-
strated elevated plasma FGF23 levels, nephrotox-
icity induced by saccharated ferric oxide and Cd
may demonstrate a similar molecular pathway.
The results of the present study suggest that the
pathway through which Cd induces renal failure
and bone abnormalities may be associated with the
Npt2c/FGF23/Klotho system. Thus, the present
The Journal of Medical Investigation Vol. 57 February 2010 105
study may serve as a useful tool for furthering our
understanding of the pathways governing Cd intoxi-
cation. In addition, these studies may also be help-
ful in the clarification of Npt2c/FGF23/Klotho sys-
tem function.
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